SACT-1 is under clinical development by Aptorum Group and currently in Phase I for Neuroblastoma. According to GlobalData, Phase I drugs for Neuroblastoma have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SACT-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SACT-1 overview

SACT-1 is under development for the treatment of neuroblastoma and other solid tumors including colorectal and triple negative cancer. The therapeutic candidate is administered orally. It is being developed based on SMART ACT Platform. The drug candidate is a repurposed drug. It acts by targeting MYCN gene.

Aptorum Group overview

Aptorum Group is a pharmaceutical company dedicated to the development of therapeutic assets to treat diseases with unmet medical needs. The company is headquartered in Hong Kong.

For a complete picture of SACT-1’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.